Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Medrxiv : the Preprint Server for Health Sciences|October 6, 2021
Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant SurgeLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
Nature Medicine|August 31, 2023
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSpyros Chalkias, Jordan L Whatley, Frank Eder, et al.
Journal of Medicinal Chemistry|April 16, 2004
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymeraseAnne B Eldrup, Charles R Allerson, C Frank Bennett, et al.
The Journal of Infectious Diseases|May 10, 2022
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialHana M El Sahly, Lindsey R Baden, Brandon Essink, et al.
Antimicrobial Agents and Chemotherapy|September 25, 2004
A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic propertiesDavid B Olsen, Anne B Eldrup, Linda Bartholomew, et al.
Science (New York, N.Y.)|October 13, 2018
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapyRazvan Cristescu, Robin Mogg, Mark Ayers, et al.
Nature Communications|August 29, 2024
Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phasesLindsey R Baden, Hana M El Sahly, Brandon Essink, et al.
The Journal of Biological Chemistry|September 11, 2003
Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitroGiovanni Migliaccio, Joanne E Tomassini, Steven S Carroll, et al.
The New England Journal of Medicine|May 11, 2022
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of AgeC Buddy Creech, Evan Anderson, Vladimir Berthaud, et al.
The Journal of Infectious Diseases|June 18, 2024
Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older AdultsJaya Goswami, Abdullah H Baqui, Pablo A Doreski, et al.
Pageof 16